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Dr. Roth replies: Kast and Altschuler propose 
the intriguing hypothesis that since methysergide, 
which is a prodrug for the potent 5-HT2B agonist 
methylergonovine,1,2 is associated with retroperi-
toneal fibrosis, the cause of this condition may be 
5-HT2B agonism. This is an interesting idea, and 
there have been many case reports and other stud-
ies linking the use of pergolide with an increased 
incidence of retroperitoneal fibrosis,3 although we 
await definitive evidence. Kast and Altschuler also 
suggest that certain atypical antipsychotic drugs 
such as risperidone and ziprasidone might be used 
for prophylaxis in the rare circumstance when a 
drug with 5-HT2B agonism cannot be avoided. (Ris-
peridone and ziprasidone have Ki values of 41.5 nM 
and 27 nM, respectively, according to the Psycho-
active Drug Screening Program’s Ki database, avail-
able at http://pdsp.med.unc.edu/pdsp.php.) The ab-
solute affinities of these drugs are rather low, and 
atypical antipsychotic drugs are costly medications 
with a large number of potentially serious side ef-
fects. Instead, I would recommend cyproheptadine, 
which is a generic, high-affinity 5-HT2B antagonist 
with a Ki value of 1.4 nM, according to the above-
mentioned database.
Ziegler and Bukhman wonder whether there 
might be some association among various 5-HT2B–
receptor polymorphisms, eosinophilia, dietary 
tryptophan, and endomyocardial fibrosis. This is 
another interesting idea worthy of further study.
Sartiani et al. suggest an interesting model 
in which cardiac stem cells might be recruited 
through 5-HT2B activation. After recruitment, fur-
ther 5-HT2B stimulation presumably would induce 
overgrowth and fibrosis. My colleagues and I have 
previously reported that 5-HT2B–receptor activa-
tion induces mitogenesis in human cardiac-valve 
interstitial cells in vitro, so there is merit to the 
idea that 5-HT2B–receptor activation may induce 
mitogenesis of cardiac-valve cells. Sartiani et al. 
also show that what appears to be 5-HT2B–recep-
tor mRNA is present in embryonic stem cells, but 
they do not provide evidence of functioning 5-HT2B 
receptors in these cells. Although their hypothe-
sis is intriguing, it will be important to demon-
strate the presence of functional 5-HT2B receptors, 
since we have frequently found that the presence 
of receptor mRNA does not always indicate func-
tional receptor protein.4
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